Patents by Inventor Christian Gege

Christian Gege has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thiazoles as modulators of ROR?t
    Patent number: 10080744
    Abstract: The present invention comprises compounds of Formula I wherein: R1, R2, R3, R4, R5, R7, R8, and {circle around (A)} are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: September 25, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue
  • FXR (NR1H4) modulating compounds
    Patent number: 9938278
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: April 10, 2018
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Christian Gege, Claus Kremoser, Olaf Kinzel, Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Aaron C. Schmitt, William J. Watkins, Jianjun Xu
  • FXR (NR1H4) modulating compounds
    Patent number: 9932332
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: April 3, 2018
    Assignee: GILEAD SCIENCES, INC.
    Inventor: Christian Gege
  • THIAZOLES AS MODULATORS OF RORyt
    Publication number: 20180064690
    Abstract: The present invention comprises compounds of Formula I wherein: R1, R2, R3, R4, R5, R7, R8, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: November 14, 2017
    Publication date: March 8, 2018
    Inventors: Steven Goldberg, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue
  • Thiazoles as modulators of ROR?t
    Patent number: 9861618
    Abstract: The present invention comprises compounds of Formula I wherein: R1, R2, R3, R4, R5, R7, R8, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: January 9, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann
  • Trifluoromethyl alcohols as modulators of ROR?t
    Patent number: 9850236
    Abstract: The present invention comprises compounds of Formula I. wherein: X, A1, A2, A3, A4, R1, R2, and R3 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 26, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Virginia Tanis, Olaf Kinzel, Christian Gege, Christoph Steeneck, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue
  • Amide substituted thiazoles as modulators of RORyt
    Patent number: 9845319
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R5, A1, A2, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 19, 2017
    Assignee: Janssen Pharmaceutiuca NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Virginia Tanis, Maud Urbanski, Aihua Wang, David Kummer, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann, Anne M. Fourie, Xiaohua Xue
  • FXR (NR1H4) MODULATING COMPOUNDS
    Publication number: 20170355685
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: June 9, 2017
    Publication date: December 14, 2017
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • FXR (NR1H4) MODULATING COMPOUNDS
    Publication number: 20170355694
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: June 12, 2017
    Publication date: December 14, 2017
    Inventor: Christian Gege
  • FXR (NR1H4) MODULATING COMPOUNDS
    Publication number: 20170355693
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: June 12, 2017
    Publication date: December 14, 2017
    Inventors: Peter A. Blomgren, Kevin S. Currie, Julie Farand, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
    Publication number: 20170327492
    Abstract: The present invention comprises methods of making 5-(2,3-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2-hydroxy-2-methylpropyl)-4-(R1-1-carbonyl)thiazole-2-carboxamide, wherein R1 is defined in the specification.
    Type: Application
    Filed: July 31, 2017
    Publication date: November 16, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Olaf Kinzel, Christian Gege, Christoph Steeneck, Gerald Kleymann, Thomas Hoffmann
  • Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR?, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
    Patent number: 9815851
    Abstract: The invention provides modulators for the orphan nuclear receptor ROR? and methods for treating ROR? mediated diseases by administrating these novel ROR? modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo carboxamide compounds of Formula (1) and the enantiomers, diastereomers, N-oxides, tautomers, solvates and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: November 14, 2017
    Assignee: Phenex Pharmaceuticals AG
    Inventors: Christoph Steeneck, Olaf Kinzel, Christian Gege, Gerald Kleymann, Thomas Hoffmann
  • NOVEL FXR (NR1H4) MODULATING COMPOUNDS
    Publication number: 20170298068
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: December 16, 2015
    Publication date: October 19, 2017
    Inventors: CHRISTIAN GEGE, Claus Kremoser, Olaf Kinzel, Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Aaron C. Schmitt, William J. Watkins, Jianjun Xu
  • Hydroxy containing FXR (NR1H4) modulating compounds
    Patent number: 9751874
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: September 5, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Christian Gege, Olaf Kinzel, Claus Kremoser, Aaron C. Schmitt
  • Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ROR?
    Patent number: 9458104
    Abstract: The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: October 4, 2016
    Assignee: Phenex Pharmaceuticals AG
    Inventors: Christian Gege, Olaf Kinzel, Christoph Steeneck, Gerald Kleymann, Thomas Hoffmann
  • HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS
    Publication number: 20160176861
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 23, 2016
    Inventors: Christian Gege, Olaf Kinzel, Claus Kremoser, Aaron C. Schmitt
  • AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORyt
    Publication number: 20160122335
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R5, A1, A2, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: October 30, 2015
    Publication date: May 5, 2016
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Virginia Tanis, Maud Urbanski, Aihua Wang, David Kummer, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann
  • THIAZOLES AS MODULATORS OF RORyt
    Publication number: 20160120850
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R7, R8, and are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: October 30, 2015
    Publication date: May 5, 2016
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Christoph Steeneck, Christian Gege, Olaf Kinzel, Gerald Kleymann, Thomas Hoffmann
  • TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt
    Publication number: 20160122336
    Abstract: The present invention comprises compounds of Formula I. wherein: X, A1, A2, A3, A4, R1, R2, and R3 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: October 30, 2015
    Publication date: May 5, 2016
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Hariharan Venkatesan, Virginia Tanis, Olaf Kinzel, Christian Gege, Christoph Steeneck, Gerald Kleymann, Thomas Hoffmann
  • CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA
    Publication number: 20150344423
    Abstract: The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 29, 2013
    Publication date: December 3, 2015
    Inventors: Christian GEGE, Olaf KINZEL, Christoph STEENECK, Gerald KLEYMANN, Thomas HOFFMANN